BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Yu J, Ohuchida K, Mizumoto K, Ishikawa N, Ogura Y, Yamada D, Egami T, Fujita H, Ohashi S, Nagai E, Tanaka M. Overexpression of c-met in the early stage of pancreatic carcinogenesis; altered expression is not sufficient for progression from chronic pancreatitis to pancreatic cancer. World J Gastroenterol 2006; 12(24): 3878-3882 [PMID: 16804974 DOI: 10.3748/wjg.v12.i24.3878]
URL: https://www.wjgnet.com/1007-9327/full/v12/i24/3878.htm
Number Citing Articles
1
Chiara Modica, Dora Tortarolo, Paolo M. Comoglio, Cristina Basilico, Elisa Vigna. MET/HGF Co-Targeting in Pancreatic Cancer: A Tool to Provide Insight into the Tumor/Stroma CrosstalkInternational Journal of Molecular Sciences 2018; 19(12): 3920 doi: 10.3390/ijms19123920
2
Zhengchao Zhang, Dong Li, Heng Yun, Jie Tong, Wei Liu, Keqiang Chai, Tongwei Zeng, Zhenghua Gao, Yongqiang Xie. Opportunities and challenges of targeting c-Met in the treatment of digestive tumorsFrontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.923260
3
Dietrich A. Ruess, Kivanc Görgülü, Sonja M. Wörmann, Hana Algül. Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging ConceptsDrugs & Aging 2017; 34(5): 331 doi: 10.1007/s40266-017-0453-y
4
Julianna Padavano, Rebecca S. Henkhaus, Hwudaurw Chen, Bethany A. Skovan, Haiyan Cui, Natalia A. Ignatenko. Mutant K-RAS Promotes Invasion and Metastasis in Pancreatic Cancer through GTPase Signaling PathwaysCancer Growth and Metastasis 2015; : CGM.S29407 doi: 10.4137/CGM.S29407
5
Agnieszka A. Rucki, Qian Xiao, Stephen Muth, Jianlin Chen, Xu Che, Jennifer Kleponis, Rajni Sharma, Robert A. Anders, Elizabeth M. Jaffee, Lei Zheng. Dual Inhibition of Hedgehog and c-Met Pathways for Pancreatic Cancer TreatmentMolecular Cancer Therapeutics 2017; 16(11): 2399 doi: 10.1158/1535-7163.MCT-16-0452
6
Kuttiappan Anitha, Kamal Dua, Dinesh Kumar Chellappan, Gaurav Gupta, Sachin Kumar Singh, Sabapathi Mohana Lakshmi, Shvetank Bhatt. HGF/c-MET: A Potential Target for the Treatment of Various CancersCurrent Enzyme Inhibition 2023; 19(2): 71 doi: 10.2174/1573408019666230227101036
7
Zhi-Yuan Mao, Guang-Qing Zhu, Li Ren, Xiao-Chuan Guo, Dan Su, Li Bai. Prognostic Value of C-met Expression in CholangiocarcinomaTechnology in Cancer Research & Treatment 2016; 15(2): 227 doi: 10.1177/1533034615578959
8
Wei Huang, Gang Huang, Shuxian An, Jianjun Liu. Molecular imaging of pancreatic ductal adenocarcinomaVIEW 2023; 4(5) doi: 10.1002/VIW.20230029
9
Dangran Li, Shiting Weng, Kai Zeng, Hanmiao Xu, Wenyueyang Wang, Jinsong Shi, Jinghua Chen, Chen Chen. Long non-coding RNAs and tyrosine kinase-mediated drug resistance in pancreatic cancerGene 2024; 895: 148007 doi: 10.1016/j.gene.2023.148007
10
Jianliang Zhang, Steven N. Hochwald. Targeting Receptor Tyrosine Kinases in Solid TumorsSurgical Oncology Clinics of North America 2013; 22(4): 685 doi: 10.1016/j.soc.2013.06.010
11
Loganayaki Periyasamy, Sneha Krishnamoorthy, Bharathi Muruganantham, Ilangovan Ramachandran, Sridhar Muthusami. Cancer Stem Cells and Signaling Pathways2024; : 207 doi: 10.1016/B978-0-443-13212-4.00012-X
12
Ming Quan, Peipei Wang, Jiujie Cui, Yong Gao, Keping Xie. The roles of FOXM1 in pancreatic stem cells and carcinogenesisMolecular Cancer 2013; 12(1) doi: 10.1186/1476-4598-12-159
13
Motahareh Mortazavi, Masoomeh Eskandari, Fatemeh Moosavi, Tahereh Damghani, Mehdi Khoshneviszadeh, Somayeh Pirhadi, Luciano Saso, Najmeh Edraki, Omidreza Firuzi. Novel quinazoline-1,2,3-triazole hybrids with anticancer and MET kinase targeting propertiesScientific Reports 2023; 13(1) doi: 10.1038/s41598-023-41283-2
14
Kristen S. Hill, Ivana Gaziova, Lindsay Harrigal, Yvette A. Guerra, Suimin Qiu, Sarita K. Sastry, Thiruvengadam Arumugam, Craig D. Logsdon, Lisa A. Elferink, Surinder K. Batra. Met Receptor Tyrosine Kinase Signaling Induces Secretion of the Angiogenic Chemokine Interleukin-8/CXCL8 in Pancreatic CancerPLoS ONE 2012; 7(7): e40420 doi: 10.1371/journal.pone.0040420
15
Afsane Bahrami, Soodabeh Shahidsales, Majid Khazaei, Majid Ghayour‐Mobarhan, Mina Maftouh, Seyed Mahdi Hassanian, Amir Avan. C‐Met as a potential target for the treatment of gastrointestinal cancer: Current status and future perspectivesJournal of Cellular Physiology 2017; 232(10): 2657 doi: 10.1002/jcp.25794
16
Zhaohui Chen, Pengbiao Miao, Hongcao Lin, Yanan Lu. AHNAK2 Promotes the Progression of Pancreatic Ductal Adenocarcinoma by Maintaining the Stability of c-METCancer Management and Research 2024; : 431 doi: 10.2147/CMAR.S451486
17
Jacek Śmigielski, Łukasz Piskorz, Renata Talar -Wojnarowska, Ewa Malecka-Panas, Sławomir Jabłoński, Marian Brocki. The estimation of metaloproteinases and their inhibitors blood levels in patients with pancreatic tumorsWorld Journal of Surgical Oncology 2013; 11(1) doi: 10.1186/1477-7819-11-137
18
Zobeida Cruz-Monserrate, Suimin Qiu, B Mark Evers, Kathleen L O'Connor. Upregulation and redistribution of integrin α6β4 expression occurs at an early stage in pancreatic adenocarcinoma progressionModern Pathology 2007; 20(6): 656 doi: 10.1038/modpathol.3800782
19
Yao Liu, Qiaoyan Li, Liwei Zhu. Expression of the Hepatocyte Growth Factor and C-Met in Colon Cancer: Correlation with Clinicopathological Features and Overall SurvivalTumori Journal 2012; 98(1): 105 doi: 10.1177/030089161209800115
20
Katarzyna Gardian, Sława Janczewska, Marek Durlik. Microenvironment Elements Involved in the Development of Pancreatic Cancer TumorGastroenterology Research and Practice 2012; 2012: 1 doi: 10.1155/2012/585674
21
Sadaf Ghanaatgar-Kasbi, Shadi Khorrami, Amir Avan, Seyed A. Aledavoud, Gordon A. Ferns. Targeting the C-MET/HGF Signaling Pathway in Pancreatic Ductal AdenocarcinomaCurrent Pharmaceutical Design 2019; 24(39): 4619 doi: 10.2174/1381612825666190110145855
22
Jun Yu, Kenoki Ohuchida, Kohei Nakata, Kazuhiro Mizumoto, Lin Cui, Hayato Fujita, Hiroshi Yamaguchi, Takuya Egami, Hidehisa Kitada, Masao Tanaka. LIM only 4 is overexpressed in late stage pancreas cancerMolecular Cancer 2008; 7(1) doi: 10.1186/1476-4598-7-93
23
Hong Hua Yan, Kyung Hee Jung, Mi Kwon Son, Zhenghuan Fang, Soo Jung Kim, Ye-Lim Ryu, Juyoung Kim, Mi-Hyun Kim, Soon-Sun Hong. Crizotinib Exhibits Antitumor Activity by Targeting ALK Signaling not c-MET in Pancreatic CancerOncotarget 2014; 5(19): 9150 doi: 10.18632/oncotarget.2363
24
Tony C. Y. Pang, Zhihong Xu, Alpha Raj Mekapogu, Srinivasa Pothula, Therese Becker, Susan Corley, Marc R. Wilkins, David Goldstein, Romano Pirola, Jeremy Wilson, Minoti Apte. HGF/c-Met Inhibition as Adjuvant Therapy Improves Outcomes in an Orthotopic Mouse Model of Pancreatic CancerCancers 2021; 13(11): 2763 doi: 10.3390/cancers13112763
25
Lin Xing, Linlin Lv, Jiaqi Ren, Hao Yu, Xinya Zhao, Xin Kong, Hong Xiang, Xufeng Tao, Deshi Dong. Advances in targeted therapy for pancreatic cancerBiomedicine & Pharmacotherapy 2023; 168: 115717 doi: 10.1016/j.biopha.2023.115717
26
Kozo Noguchi, Masamitsu Konno, Hidetoshi Eguchi, Koichi Kawamoto, Ryouta Mukai, Naohiro Nishida, Jun Koseki, Hiroshi Wada, Hirofumi Akita, Taroh Satoh, Shigeru Marubashi, Hiroaki Nagano, Yuichiro Doki, Masaki Mori, Hideshi Ishii. c‑Met affects gemcitabine resistance during carcinogenesis in a mouse model of pancreatic cancerOncology Letters 2018;  doi: 10.3892/ol.2018.8793
27
Penelope Edwards, Byung Woog Kang, Ian Chau. Targeting the Stroma in the Management of Pancreatic CancerFrontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.691185
28
Yuyuan Chen, Kunihiko Morihiro, Yui Nemoto, Akito Ichimura, Ryosuke Ueki, Shinsuke Sando, Akimitsu Okamoto. Selective inhibition of cancer cell migration using a pH-responsive nucleobase-modified DNA aptamerChemical Science 2024; 15(41): 17097 doi: 10.1039/D4SC04424J
29
Yangbing Jin, Zehui Zhang, Siyi Zou, Fanlu Li, Hao Chen, Chenghong Peng, Xiaxing Deng, Chenlei Wen, Baiyong Shen, Qian Zhan. A Novel c-MET-Targeting Antibody-Drug Conjugate for Pancreatic CancerFrontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.634881